FIELD: medicine.
SUBSTANCE: thymus-specific protein T101 consisting of 84 amino acids is recovered from human thymus. The recovered full-length peptide T101 includes the signal peptide consisting of 33 amino acids and the peptide sequence T101 consisting of 51 amino acids and exhibiting immunomodulating activity. The full-length peptide T101, and also peptide fragments and derivatives are used as a part of a pharmaceutical composition for treating autoimmune and inflammatory diseases.
EFFECT: invention allows preparing polypeptide capable to stimulate lymphocyte proliferation of human peripheral blood, to inhibit the tumour growth and to modulate the immune system.
10 cl, 15 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THYMUS-SPECIFIC PROTEIN | 2005 |
|
RU2535971C2 |
| GASTROINTESTINAL PROLIFERATIVE FACTOR AND ITS APPLICATIONS | 2005 |
|
RU2343158C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
| RECOMBINANT PROTEIN REC-MP, CONTAINING SEQUENCE OF MYELOPEPTIDES FOR TREATING SECONDARY IMMUNODEFICIENCY CONDITIONS | 2014 |
|
RU2585494C2 |
| FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| MEDICATION, INTENDED FOR TREATMENT AND/OR PREVENTION OF AUTOIMMUNE DISEASE AND FOR FORMATION OF REGULATORY N-CELLS | 2009 |
|
RU2531936C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
